4D Molecular Therapeutics, Inc. FDMT 深 沪
等待开盘 08-10 09:30:00 美东时间
10.75
+0.200
+1.90%
华盛通- 最 高10.84
- 今 开10.66
- 成交量 32.84万股
- 最 低 10.06
- 昨 收 10.55
- 总市值 3.47亿
- 52周最高 14.00
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 5.97
- 委 比 10.35%
- 总股本 3229.98万
- 历史最高 55.11
- 量 比 0.64
- 振 幅 7.39%
- 历史最低 1.10
- 每 手 1
- 风险率 1.62%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多4D Molecular's One-Shot Eye Therapy Delivers Two-Year Win
4D Molecular Therapeutics reports positive 2-year Phase 2b data for 4D-150 in wet AMD, showing up to an 87% cut in treatment burden.
07-20 21:05
4D Molecular Therapeutics Completes Patient Enrollment In 4FRONT-1 Trial Evaluating 4D-150
4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT, or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide
02-09 21:12
4DMT to Participate in Upcoming Investor Conferences
4D Molecular Therapeutics announced its participation in Jefferies and Goldman Sachs healthcare conferences in June 2025, with details on dates, times, and webcast links provided. The company is focused on developing innovative therapies for retinal diseases and cystic fibrosis.
2025-05-28 12:00
4DMT Highlights Clinical Activity For 4D-150 And Design Of 4FRONT Phase 3 Program At 4D-150 Wet AMD Development Day
4D-150 demonstrated robust and durable clinical activity across all wet age-related macular degeneration (wet AMD) patient populations based on longest available follow-up dataIn broad population (Phase 2b), 70%
2024-09-19 04:07
The Latest Analyst Ratings For 4D Molecular Therapeutics
4D Molecular Therapeutics (NASDAQ:FDMT) underwent analysis by 5 analysts in the...
2024-09-10 02:01
Cantor Fitzgerald Reiterates Overweight on 4D Molecular Therapeutics
Cantor Fitzgerald analyst Josh Schimmer reiterates 4D Molecular Therapeutics (NASDAQ:FDMT) with a Overweight.
2024-09-10 01:03
